Natera Inc is a biotechnology company that focuses on providing innovative genetic testing services for various medical applications
The company specializes in non-invasive prenatal testing, environmental DNA analysis, and oncology, utilizing advanced genetic insights to aid in disease detection and management. By leveraging its proprietary technology and bioinformatics, Natera aims to improve patient outcomes and facilitate personalized medicine through comprehensive genomic solutions that empower healthcare providers and patients alike.
Genetic testing company Natera (NASDAQNTRA). reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 53% year on year to $476.1 million. The company’s full-year revenue guidance of $1.91 billion at the midpoint came in 5.8% above analysts’ estimates. Its GAAP loss of $0.41 per share was 9.3% below analysts’ consensus estimates.
Billionaire investor Stanley Druckenmiller's family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent 13-F filing.
Exploring NATERA INC's Technical Signals and Breakout Potential: A technical analysis of NATERA INC (NASDAQNTRA) shows it may be setting up for a breakout.
In this video lesson, I review the resilient overall market, stocks on my radar for the short and long-term portfolio, and a new EOD swing trade, for Tuesday's session. Happy trading. Aloha.
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these spaces.
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX, NVO, and BMRN.
Druckenmiller's Duquesne Family Office sold Nvidia and Palantir stocks while increasing stake in Teva Pharmaceutical, signaling a shift in investment focus.
